Clinical information, CD38 expression, and response to surface IgM engagement
Case ID . | Sex/age (y) . | Illness duration (y) . | WBC (× 103/μL) . | Purification (%) . | CD38+ (%) . | IgM-mediated apoptosis inhibition (%)* . |
---|---|---|---|---|---|---|
31 | M/74 | 3.5 | 158 | 94 | 45 | − 2.4 |
47 | F/78 | 6 | 102 | 96 | 33 | 13 |
58 | F/80 | 6 | 50 | 90 | 44 | 47 |
69 | F/80 | 8 | 142 | 91 | 3.3 | 17 |
72 | M/43 | 7 | 106 | 96 | 20.4 | 19 |
78 | M/57 | 2.5 | 37.8 | 90 | 34 | 27 |
86 | M/76 | 5 | 72.9 | 85 | 10.5 | − 6.1 |
89 | M/82 | 10 | 26.2 | 87 | 1.7 | − 3.7 |
96 | M/48 | 12 | 69.5 | 97 | 2.1 | 14.5 |
104 | M/70 | 10 | 79.1 | 86 | 91 | 12.6 |
106 | F/65 | 9 | 69.7 | 93 | ND | 1.8 |
108 | M/66 | 7 | 52.5 | 79 | 96 | 13.3 |
111 | F/60 | 3 | 136.9 | 92 | .1 | 18.1 |
114 | M/52 | < 1 | 216 | 95 | 16 | 15.6 |
121 | F/79 | 11 | 68 | 67 | 17 | 13 |
Case ID . | Sex/age (y) . | Illness duration (y) . | WBC (× 103/μL) . | Purification (%) . | CD38+ (%) . | IgM-mediated apoptosis inhibition (%)* . |
---|---|---|---|---|---|---|
31 | M/74 | 3.5 | 158 | 94 | 45 | − 2.4 |
47 | F/78 | 6 | 102 | 96 | 33 | 13 |
58 | F/80 | 6 | 50 | 90 | 44 | 47 |
69 | F/80 | 8 | 142 | 91 | 3.3 | 17 |
72 | M/43 | 7 | 106 | 96 | 20.4 | 19 |
78 | M/57 | 2.5 | 37.8 | 90 | 34 | 27 |
86 | M/76 | 5 | 72.9 | 85 | 10.5 | − 6.1 |
89 | M/82 | 10 | 26.2 | 87 | 1.7 | − 3.7 |
96 | M/48 | 12 | 69.5 | 97 | 2.1 | 14.5 |
104 | M/70 | 10 | 79.1 | 86 | 91 | 12.6 |
106 | F/65 | 9 | 69.7 | 93 | ND | 1.8 |
108 | M/66 | 7 | 52.5 | 79 | 96 | 13.3 |
111 | F/60 | 3 | 136.9 | 92 | .1 | 18.1 |
114 | M/52 | < 1 | 216 | 95 | 16 | 15.6 |
121 | F/79 | 11 | 68 | 67 | 17 | 13 |
ID indicates identification number; WBC, white blood cell count; ND, not done.
Apoptosis inhibition reflects the absolute difference between the percentage of annexin V-binding cells after culture with medium or anti-IgM F(ab′)2 fragments for 48 hours. Positive values indicate inhibition of apoptosis; negative values indicate enhancement of apoptosis.